Change in the area of premalignant lesions is an end point in estimating the efficacy of chemopreventive agents. When examiners round measurements of lesion length and width, they introduce variability, which perturbs the relative percent change in lesion area and, consequently, the percent of subjects showing a clinical response. We use simulations to illustrate the resulting bias when the age...

In clinic, oral leukoplakia (OLK) may develop into oral cancer. However, the mechanism underlying this transformation is still unclear. In this work, we present a new pipeline to identify oral cancer related genes and microRNAs (miRNAs) by integrating both gene and miRNA expression profiles. In particular, we find some network modules as well as their miRNA regulators that play important roles ...

To the Editor: The article by William et al. (1) reports the lack of activity of high-dose fenretinide (1,800 mg/m/d, given as 900 mg/m twice daily) in patients with oral leukoplakia. The same authors had previously shown that a lower dose of fenretinide (i.e., 200 mg/d, once daily) for 3 months was effective (34% partial responses) with a trough drug concentration in plasma at steady state (Cs...

background and aims. many oral squamous cell carcinomas develop from potentially malignant disorders (pmds) which include a variety of lesions and conditions characterized by an increased risk for malignant transformation. this study evaluated the quantitative expression of egfr in normal oral mucosa, oral leukoplakia and oral submucous fibrosis to predict the malignant risk in compliance with ...

introduction: leukoplakia is the most common precancerous lesion of the oral mucosa and may range microscopically form benign hyperkeratosis to invasive squamous cell carcinoma. p53 is a tumor suppressor protein; whereas, proliferative cell nuclear antigen (pcna) is a proliferative marker. the aim of this study was to evaluate the immunohistochemical expressions of p53 and pcna in oral leukopla...

The aim of this paper was to assess the nonsurgical treatment of oral leukoplakia (OL). A medline search from 1983 to 2009 was conducted. The topical or systemic nonsurgical treatments or combination of both was reviewed. The primary outcomes of interest were clinical resolution, malignant transformation, follow-up, and recurrence of OL. Studies showed a rate higher than 50% of clinical resolut...